Jennison Associates LLC Editas Medicine, Inc. Transaction History

Jennison Associates LLC

$155 Billion
Q2 2024

A detailed history of Jennison Associates LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Jennison Associates LLC holds 124,888 shares of EDIT stock, worth $419,623. This represents 0.0% of its overall portfolio holdings.

Number of Shares

124,888

Previous 106,520 17.24%

Holding current value

$419,623

Previous $790,000 26.2%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$4.67 - $7.28 $85,778 - $133,719	18,368 Added 17.24%	124,888 $583,000
Q1 2024 May 02, 2024	BUY	$7.03 - $11.07 $168,720 - $265,680	24,000 Added 29.08%	106,520 $790,000
Q4 2023 Feb 01, 2024	SELL	$6.25 - $11.11 $64,250 - $114,210	-10,280 Reduced 11.08%	82,520 $835,000
Q3 2023 Oct 31, 2023	SELL	$6.92 - $9.31 $172,868 - $232,573	-24,981 Reduced 21.21%	92,800 $723,000
Q2 2023 Aug 03, 2023	BUY	$6.36 - $11.47 $139,455 - $251,502	21,927 Added 22.88%	117,781 $969,000
Q1 2023 Apr 26, 2023	BUY	$7.03 - $11.53 $20,928 - $34,324	2,977 Added 3.21%	95,854 $694,000
Q4 2022 Feb 09, 2023	BUY	$8.32 - $13.21 $303,538 - $481,940	36,483 Added 64.69%	92,877 $823,000
Q3 2022 Nov 01, 2022	SELL	$12.16 - $19.42 $89,740 - $143,319	-7,380 Reduced 11.57%	56,394 $690,000
Q2 2022 Aug 02, 2022	BUY	$9.99 - $21.35 $110,499 - $236,152	11,061 Added 20.98%	63,774 $754,000
Q1 2022 May 11, 2022	BUY	$14.08 - $27.63 $742,199 - $1.46 Million	52,713 New	52,713 $1 Million

Others Institutions Holding EDIT

# of Institutions

248

Shares Held

58.8M

Call Options Held

494K

Put Options Held

417K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $231M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.

Account

Jennison Associates LLC Editas Medicine, Inc. Transaction History